Branch retinal vein occlusion with macular edema
Conditions
Interventions
Experimental group:Vitreous injection of VEGF drugs + temporal artery by subcutaneous injection of compound anisodine injection
The control group:Vitreous injection of VEGF drugs
Sponsors
Affiliated to the Capital University of Medical Sciences, Beijing Tongren Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. The diagnosis of branch retinal vein occlusion secondary macular edema, and cause visual impairment; 2. The vein occlusion duration less than 6 months; 3. Selected baseline score vision: (ETDRS) of eye best corrected vision acuities were 31 letters BCVA 80 characters or less. The contralateral eye best corrected visual acuity of 31 letters; 4. Any gender, aged 18 to 70 years; 5. Patients can accept at least two courses of compound anisodine injection treatment; 6. Understand and willing to participate in this clinical study and sign the informed consent before into the group.
Exclusion criteria
Exclusion criteria: 1. The one-eyed patients; 2. Clinical trials have any impact on the reliability of other serious eye diseases, such as serious blepharitis, conjunctivitis, keratitis, uveitis, glaucoma, clear lens turbidity, diabetes hyperplastic retinopathy, temporal artery nonarteritic ischemic optic neuropathy, macular hole, retinal detachment, retinitis pigmentosa, etc.); 3. The retinal laser photocoagulation treatment of patients; 4. The target eye for eye surgery within 3 months received before history, anti VEGF medication history, the eye or eyes using sugar cortical hormone drugs patients; 5. Serious heart, cerebrovascular disease, respiratory function, hepatic and renal dysfunction, malignant tumor, or because of body condition is not allowed to complete all inspectors; 6. Allergic to any ingredients in studying drug; Patients with procaine allergies; Fluorescence angiography allergies; 7. Unable to control high blood pressure patients (group into the screening/baseline blood pressure, systolic blood pressure > 160 MMHG, or diastolic blood pressure > 100 MMHG); 8. Light feeling more than 1 week; 9. Women in pregnancy or lactation; 10. The group of the first 3 months to participate in other clinical trials; 11. There are other unfavorable for drug clinical test subjects.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BCVA; | — |
Countries
China
Contacts
Public ContactWei Wenbin
Affiliated to the Capital University of Medical Sciences, Beijing Tongren Hospital
Outcome results
None listed